Andere talen Cadrenal Therapeutics, Inc.

Aandelen

CVKD

US1276361086

Beurs gesloten - Nasdaq Andere beurzen 22:30:00 24-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,4106 ^USD	-2,00%		-0,10%	-44,51%

09/05	Cadrenal Therapeutics, Inc. rapporteert winstresultaten voor het eerste kwartaal dat eindigde op 31 maart 2024	CI
09/04	Cadrenal Therapeutics ontvangt de FDA Orphan Drug Designation voor Tecarfarin voor de preventie van trombo-embolie en trombose bij patiënten met LVAD's, RVAD's, biventriculaire assistentietoestellen en totale kunstharten.	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024	23/05
Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update	09/05
Cadrenal Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024	11/04
Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts	09/04
Cadrenal Therapeutics Gets FDA Orphan Drug Designation for Tecarfarin	09/04
Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts	09/04
Cadrenal Therapeutics Files $100 Million Mixed Shelf; Shares Fall	12/03
Cadrenal Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	11/03
CADRENAL THERAPEUTICS TO PARTICIPATE AT TECHNOLOGY AND HEART FAILURE THERAPEUTICS CONFERENCE	27/02
Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference	26/02
Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial	08/02
Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer	08/02
Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024	24/01
Certain Warrants of Cadrenal Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 20-JAN-2024.	20/01
Certain Common Stock of Cadrenal Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 20-JAN-2024.	20/01
Certain Stock Options of Cadrenal Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 20-JAN-2024.	20/01
Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare Conference	04/01
Noble Capital Markets Initiates Coverage on Cadrenal Therapeutics with Outperform Rating and US$4.00 Price Target	19/12
Cadrenal Therapeutics Engages The Sage Group to Advance Tecarfarin's Late-Stage Development and Commercialization	12/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Cadrenal Therapeutics, Inc.

Aandelen

CVKD

US1276361086

Andere talen

Filters